CV Lattes
ORCID
Google Scholar Citations
Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduate at Farmácia Bioquímica from Universidade Estadual Paulista Júlio de Mesquita Filho (1987), master's at Pharmacy from Universidade de São Paulo (1995) and ph.d. at Toxicology from Universidade de São Paulo (2003). Has experience in Pharmacology, focusing on Toxicology, acting on the following subjects: farmacocinética, toxicologia, carvedilol, idosos and etambutol. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pharmacotherapy has been extensively applied on a wide variety of diseases, is usually of lower cost and risk and is the most frequently used method in the clinic for the treatment and prevention of acute and chronic diseases. It is imperative that the development of therapeutic alternatives occurs continuously, since new pandemics present themselves in modern times. The life expectancy o…
Poor pharmacokinetic properties and toxicity constitute more than 50% of important causes of costly late-stage failures in drug development to produce alternative therapies for humans. Thus, the pharmacokinetics should be evaluated earlier in the drug development, for the simultaneous improvement of the pharmacokinetics and pharmacological potency that may result in a more promising candi…
Chagas disease is an illness that affects millions of people worldwide, especially in developing countries. It is caused by the parasite Trypanosoma cruzi, which causes serious harm to the host, particularly in cardiac tissue. In Brazil, the only drug available to treat Chagas disease is benznidazole. The drug is administered only as immediate release tablets of 100 mg (Ministry of Health…
(Only some records are available in English at this moment)
The improvement of technologies in analysis and synthesis, structural characterization and the introduction of combinatorial chemistry promoted an acceleration in obtaining new synthetic compounds. Early evaluations of pharmacokinetic properties through in vitro assays provide notions of absorption, allowing preliminary screening by excluding less promising candidates and direct investmen…
Metabolic instability is one of the main pharmacokinetic processes whose inadequate characteristics may impair the development of a drug candidate, since it affects parameters such as clearance, half-life and bioavailability, and is also related to toxicity. In vitro metabolism assay may be performed with cells or cell animal model in which the pharmacokinetic assay is planned, or with ce…
Vitamin D has been used in the treatment and prevention of both osteoporosis and osteomalacia. The deficiency of vitamin D is related to several autoimmune diseases and therapeutic protocols, therefore, long term high doses of vitamin D are used for the treatment of these diseases. The therapeutic use of vitamin D must be controlled in order to avoid its main adverse effects - hypercalcem…
(Only some records are available in English at this moment)
The Laboratory of Preclinical Pharmacokinetics of New Drugs and Medicines is a research group involved in the pharmacokinetics study of new drugs in Brazil. Many new compounds are found with unfavourable pharmacokinetics characteristics despite observable pharmacologic effect. The explanation may be in the metabolites of these drugs, therefore the study of these products will improve the …
Sickle cell disease is the most common and severe monogenic disorder worldwide. It is characterized by episodes of acute disability and progressive organ damage. In order to treat the symptoms of this disease, a phtalimide derivative, LAPDESF-SCD03, was planned to have nitric oxide donor activity and anti-inflammatory activity, which has been shown in published studies. The characterizati…
| 5 / 5 | Completed research grants |
| 20 / 15 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 27 / 22 | All research grants and scholarships |
| Associated processes | |